Trial reportIndian journal of ophthalmology2022
Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes.
Trial report in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Efficacy of 0.01% low-dose atropine therapy for the myopia and premyopia in children: a meta-analysis and systematic review.BMC ophthalmology · 2026Pooled it
- A systematic review of the study design and statistical practices in randomized controlled trials on myopia treatment (2019-2023).BMC ophthalmology · 2025Pooled it
- A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children's populations.Frontiers in pharmacology · 2025Pooled it
- Myopia prevention and control in children: a systematic review and network meta-analysis.Eye (London, England) · 2023Pooled it
- Effect of low-dose atropine on young premyopic and low-myopic children: atropine treatment of myopia (ATOM3) - a randomised control trial.The British journal of ophthalmology · 2026Trial
- Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial.European journal of pediatrics · 2023Trial
- Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Low-Concentration Atropine (0.01%, 0.025%, 0.05%) for Myopia Progression in Children: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Dual-surface aberration-increasing lenses versus single-vision lenses in non-myopic children: a randomized clinical trial.Eye and vision (London, England) · 2026Article
- Identifying and Managing Pre-Myopia: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Atropine Eye Drops in Childhood Myopia Control: A Review.International journal of medical sciences · 2026Review
- Factors predicting myopia incidence in China and Europe.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Efficacy and Safety of 0.01% Atropine Eye Drops and Novel Lenslet-ARray-Integrated Spectacle Lenses for the Prevention of Myopia Progression Among Children with Premyopia: A Randomized Clinical Trial.Ophthalmology and therapy · 2025Article
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Biometric risk factors for myopia onset in emmetropic school-age children.Japanese journal of ophthalmology · 2025Article
- A nomogram for identifying premyopia and myopia candidates in Chinese children: focusing on those with cycloplegic spherical equivalent refraction ≤ + 0.75D.BMC ophthalmology · 2025Article
- Effect of optical technical of guiding emmetropization lenses on myopia prevention in children without myopia.Scientific reports · 2025Article
- What do we know about premyopia and should we be giving it greater consideration?BMJ open ophthalmology · 2025Article
- Efficacy of Myopia Prevention in At-Risk Children: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2025Review
- Cross-population validation of the PreMO risk indicator for predicting myopia onset in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLow-concentration atropine (LCA; 0.01%) is known to reduce the progression of myopia in axial myopes. The purpose of this study was to understand the role of LCA in premyopic children in preventing progression.
methodsA randomized case-control study of known premyopes was done between the use of LCA and no intervention. A total of 30 children were included in both groups.
resultsThe mean age in the LCA group was 7.7 ± 2.1 years (5-12 years), and in the control group, it was 7.2 ± 1.9 years (4-12 years). The mean baseline progression per year in the LCA group (before starting the eye drops) was - 0.72 ± 0.3 D, and in the control group, it was - 0.69 ± 0.4 D. At the end of the first year, the mean progression in the LCA group was - 0.31 ± 0.3 D versus - 0.76 ± 0.4 D, and the axial length increase was 0.12 ± 0.1 mm in the LCA group and 0.21 ± 0.2 mm in the control group. At the end of the second year, the mean progression compared with the baseline in the LCA group was - 0.6 ± 0.3 D versus - 1.75 ± 0.4 D, and the axial length showed an increase from baseline in the LCA group by 0.21 ± 0.2 mm, and in the control group, the increase was 0.48 ± 0.2 mm in 2 years.
conclusionLow-concentration eye drops (0.01%) work in preventing the progression of axial myopia in premyopic children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.